You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD1/PDL1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, Abraxane)

Active, not recruiting
  • Urothelial Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Dec 15, 2021

Cancer Trial in Besancon (Biological samples, Anti PD1/PDL1 treatment)

Recruiting
  • Cancer
  • Biological samples
  • Anti PD1/PDL1 treatment
  • Besancon, France
    University Hospital of Besançon
Jul 30, 2021

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Serial [18F]FluorodeoxyglucosePET/CT asBiomarker of Therapeutic

Terminated
  • Non-Small Cell Lung Cancer (NSCLC)
  • [18F]fluoroglucose(FDG)
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 16, 2021

Solid Tumor Trial in Richmond (Stereotactic radiotherapy, Biological: humanized anti-PD-1 mAb, Biological: humanized anti-PD-L1

Completed
Has Results
  • Solid Tumor
  • Stereotactic radiotherapy
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 20, 2021

Immune Checkpoint Inhibitors (AUTENTIC)

Recruiting
  • Cancer
  • +2 more
  • Treatment with immune checkpoint inhibitors.
  • Blood tests.
  • Vitoria, Álava, Spain
    Hospital Universitario Araba
Aug 27, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Anti-PD-L1 Monoclonal Antibody IMC-001
  • Punch Biopsy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Metastatic Renal Cell Carcinoma Trial in Milan (Cabometyx)

Completed
  • Metastatic Renal Cell Carcinoma
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale Tumori
Apr 23, 2021

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Tumor Trial in Houston

Active, not recruiting
  • Colon Adenocarcinoma
  • +10 more
  • Anti-PD-L1/TGFbetaRII Fusion Protein M7824
  • Houston, Texas
    M D Anderson Cancer Center
Jan 12, 2022

Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 Trial in Scottsdale,

Active, not recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +7 more
  • Scottsdale, Arizona
  • +2 more
Nov 3, 2021

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    NSCLC, Progression, Disease Trial in Paris (Resting Energy Expenditure measurement)

    Completed
    • Non-small Cell Lung Cancer
    • Progression, Disease
    • Resting Energy Expenditure measurement
    • Paris, France
      Cochin Hospital
    May 10, 2021

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)

    Recruiting
    • Locally Advanced or Metastatic Solid Tumors
    • Non-small Cell Lung Cancer
    • Blacktown, New South Wales, Australia
    • +4 more
    May 25, 2022

    Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)

    Recruiting
    • Solid Tumor Malignancy
    • +4 more
    • mRNA-1273
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 14, 2023

    Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

    Recruiting
    • Anatomic Stage II Breast Cancer AJCC v8
    • +13 more
    • Bintrafusp Alfa
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 13, 2021

    Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

    Recruiting
    • Melanoma (Skin)
    • +4 more
    • Bloomington, Minnesota
    • +7 more
    Jan 31, 2023